Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05041959
Other study ID # K23DA042898
Secondary ID K23DA042898
Status Completed
Phase N/A
First received
Last updated
Start date June 2, 2022
Est. completion date April 15, 2024

Study information

Verified date May 2024
Source University of Oklahoma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to find out how smoking affects the way the brain responds to pleasure and how this impacts smokers' behavior. Participants will complete three sessions. The first session will be a screening and training visit to determine final eligibility. Eligible participants will work with a researcher to develop brief scripts about times when they smoke and do other activities. Next, participants will attend two magnetic resonance imaging (MRI) scans - one after abstaining from smoking for 24 hours and the other after smoking as usual. After the second MRI, participants will answer questions on their phone every day for two weeks.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date April 15, 2024
Est. primary completion date March 29, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 55 Years
Eligibility Inclusion Criteria: 1. Generally healthy 2. Age 21-55 3. Right-handed using a three-item scale 4. Daily smoker of = 6 cigarettes/day 5. Smoking regularly for = 1 year 6. Have a smartphone capable of running the MetricWire application 7. Able to read and understand English 8. Able to identify at least 6 pleasurable activities they do not do concurrently with smoking or associate with smoking. 9. Able to identify at least 6 unique locations/scenarios they do associate with smoking Exclusion Criteria: 1. Planning to quit smoking within the next 60 days 2. Currently seeking or receiving treatment for smoking cessation 3. Use of smokeless tobacco, nicotine replacement products or electronic cigarettes more than 5 days in the past month. 4. Breath alcohol level =.001. Participants may be allowed one reschedule at the discretion of the PI or other study staff. 5. Positive toxicology screen for illicit drugs 1. Marijuana will be tested for but will not be exclusionary 2. Participants failing the toxicology screen may be allowed one re-screening attempt at the PI's discretion 3. Participants with valid prescriptions who report using the medication as directed and meet all other eligibility criteria may be allowed to participate at the PI's discretion 6. Current use of antipsychotic or stimulant medications. 7. Significant health problems or those that would impact scientific goals of the project, including (but not limited to): 1. Cancer, Bronchitis, Emphysema, COPD 2. Asthma or Breathing Problems 3. Insulin-Dependent Diabetes 4. Heart disease, angina, heart failure, serious arrhythmia or heart attack within the past 6 months 5. Systolic Blood Pressure > 160, Diastolic Blood Pressure > 100, HR > 115 bpm (one re-screen allowed). 6. Glaucoma, color blindness or an uncorrected vision problem 7. Significant hearing loss requiring the use of hearing aids or other hearing problems that would impact 8. History of stroke, brain tumor, seizure disorder, or traumatic brain injury 9. Metal implants (e.g. pacemaker, surgical pins, certain dental repairs), dental braces, or metal fragment injuries. 10. Claustrophobia 11. Weight > 350 pounds or unable to fit in the MRI scanner bore 12. Current psychotic disorder, alcohol use disorder or drug use disorder for drugs other than cannabis (moderate or severe only, mild is allowable at PI's discretion). AUD and DUD in remission are also allowable at PI's discretion. 13. Pregnant, breastfeeding or planning to become pregnant during the course of the study (females) 8. Current enrollment in another smoking research study or having participated in a study involving daily use of Spectrum cigarettes or other reduced nicotine products within the past three months 9. Irregular sleep-wake cycles (e.g. swing-shift work, unusual sleep pattern)

Study Design


Intervention

Other:
Smoking Abstinence
Participants will abstain from smoking for 24 hours
Ad Lib Smoking
Participants will continue smoking as usual (i.e. ad lib) in the day leading up to the scan and smoke one cigarette of their own brand immediately prior to scanning.

Locations

Country Name City State
United States Hardesty Center for Clinical Research and Neuroscience Tulsa Oklahoma

Sponsors (3)

Lead Sponsor Collaborator
University of Oklahoma National Institute on Drug Abuse (NIDA), Oklahoma State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood Oxygen Level Dependent (BOLD) Activation BOLD activation in brain reward network regions Approximately 2-4 weeks
Primary Ecological Momentary Assessment (EMA) Pleasure Ratings Anticipated and experienced pleasure based on self-report ratings acquired each day during the EMA phase 2-4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05176418 - IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate Early Phase 1
Completed NCT04084210 - Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use Phase 2
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Withdrawn NCT03707600 - State and Trait Mediated Response to TMS in Substance Use Disorder N/A
Recruiting NCT03999099 - Targeting Orexin to Treat Nicotine Dependence Phase 1
Completed NCT03847155 - Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery N/A
Completed NCT02840435 - Study on Sit to Quit Phone Intervention N/A
Completed NCT02139930 - Project 2: Strategies for Reducing Nicotine Content in Cigarettes N/A
Completed NCT01982110 - A Mindfulness Based Application for Smoking Cessation N/A
Completed NCT01926626 - Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers Phase 2
Completed NCT01569490 - Striving to Quit: First Breath N/A
Withdrawn NCT01569477 - Striving to Quit-Wisconsin Tobacco Quit Line N/A
Completed NCT01685996 - Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation Phase 1/Phase 2
Completed NCT01632189 - The Effect of Varenicline on D2/D3 Receptor Binding in Smokers N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT00996034 - Nicotine Vaccination and Nicotinic Receptor Occupancy Phase 2
Completed NCT01061528 - Coping Skills Treatment for Smoking Cessation N/A
Withdrawn NCT01589081 - Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect N/A
Completed NCT01943994 - Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study N/A
Suspended NCT01636336 - Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects N/A